key: cord-0910871-bie2xgv4
authors: Piñana, José Luis; Gómez, María Dolores; Pérez, Ariadna; Madrid, Silvia; Balaguer‐Roselló, Aitana; Giménez, Estela; Montoro, Juan; González, Eva María; Vinuesa, Víctor; Moles, Paula; Hernández‐Boluda, Juan Carlos; Salavert, Miguel; Calabuig, Marisa; Sanz, Guillermo; Solano, Carlos; Sanz, Jaime; Navarro, David
title: Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections
date: 2018-06-22
journal: Transpl Infect Dis
DOI: 10.1111/tid.12926
sha: 79aca6ecc85195d85ab35ca9b11cdcca4a769545
doc_id: 910871
cord_uid: bie2xgv4

Risk factors (RFs) and mortality data of community‐acquired respiratory virus (CARVs) lower respiratory tract disease (LRTD) with concurrent pulmonary co‐infections in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is scarce. From January 2011 to December 2017, we retrospectively compared the outcome of allo‐HSCT recipients diagnosed of CARVs LRTD mono‐infection (n = 52, group 1), to those with viral, bacterial, or fungal pulmonary CARVs LRTD co‐infections (n = 15, group 2; n = 20, group 3, and n = 11, group 4, respectively), and with those having bacterial pneumonia mono‐infection (n = 19, group 5). Overall survival (OS) at day 60 after bronchoalveolar lavage (BAL) was significantly higher in group 1, 2, and 4 compared to group 3 (77%, 67%, and 73% vs 35%, respectively, P = .012). Recipients of group 5 showed a trend to better OS compared to those of group 3 (62% vs 35%, P = .1). Multivariate analyses showed bacterial co‐infection as a RF for mortality (hazard ratio[HR] 2.65, 95% C.I. 1.2‐6.9, P = .017). We identified other 3 RFs for mortality: lymphocyte count <0.5 × 10(9)/L (HR 2.6, 95% 1.1‐6.2, P = .026), the occurrence of and CMV DNAemia requiring antiviral therapy (CMV‐DNAemia‐RAT) at the time of BAL (HR 2.32, 95% C.I. 1.1‐4.9, P = .03), and the need of oxygen support (HR 8.3, 95% C.I. 2.9‐35.3, P = .004). CARV LRTD co‐infections are frequent and may have a negative effect in the outcome, in particular in the context of bacterial co‐infections.

Community-acquired respiratory viruses (CARVs) are a common cause of upper and/or lower respiratory tract infection (URTI and LRTD) after allogeneic stem cell transplantation (allo-HSCT) resulting in high morbidity and mortality, especially when the lower respiratory tract is involved. [1] [2] [3] [4] [5] [6] Recently, the introduction in daily clinical practice of more sophisticated diagnostic tools based on reverse transcription polymerase chain reaction (RT-PCR), such as those testing for CARVs and other pathogens, has permitted to expand microbiological findings in bronchoalveolar lavage (BAL) of allo-HSCT recipients harboring lower respiratory tract (LRT) complications. This fact has likely increased the ability to diagnose infectious pneumonia and probably has led to the identification of a high number of cases with co-pathogens as compared to conventional microbiological studies (ie, viral culture or antigen testing only available for some CARVs). Currently, there is a lack of studies analyzing in detail the incidence, character- To this purpose, this study analyzes the clinical implications of co-infections (viral, fungal, and bacterial CARVs LRTD coinfections) detected in BAL samples in a cohort of allo-HSCT recipients with a first-proven CARVs LRTD episode and compared the outcome to mono-infections (CARV and bacterial LRT monoinfections). Additionally, we analyzed risk factors (RFs) and the value of the immunodeficiency score index (ISI) 11 to predict morbidity and mortality in allo-HSCT recipients with CARVs LRTD in the RT-PCR era. 

Variables for immunodeficiency scoring index (ISI) 11 variables, respectively: HSCT ≤ 6 months, T-cell or B-cell depletion ≤3 months, graft versus-host disease (GVHD) grade 2 or extensive disease, neutropenia ≤ 0.5 x 10 9 /L, and lymphopenia ≤ 0.1 x 10 9 /L.

All microbiological findings from BAL samples and radiology patterns were also collected and critically reviewed. The local ethics committee approved the study and when available subjects gave their written informed consent before participating in the study.

Bronchoscopy was performed using standard procedures according to international consensus guidelines. 14 The original Basel Immunodeficiency grading score also included immunoglobulin G levels (IgG < 4 g/L). We adapted the Basel IG since immunoglobulin G levels were not available at the time of BAL in most of our patients. 

Quantitative cultures of BAL specimens for bacterial isolation were performed on conventional media as recommended 16 ; in agreement with the generally accepted thresholds, 16 

CMV DNA in plasma was quantified using the RealTime CMV PCR assay (Abbott Molecular, Des Plaines, IL, USA), which exhibits a limit of detection of approximately 31 IU/mL at the HCUV, as previously described. 17 At the HLF, the CMV R-GENE® (Biomerieux, L'Etoile, Paris, France), which displays a limit of detection of 150 IU/mL, was performed. 18 Surveillance for CMV DNAemia quantitation was conducted at least once a week within the first 100 days after allo-HSCT and at each outpatient visit while on immunosuppression at both centers. A preemptive antiviral therapy approach was used at HCUV to prevent CMV end-organ disease. 19 Patients were preemptively 

CMV DNAemia-RAT was defined as described above. Acute graft versus host disease (aGvHD) was diagnosed and graded according to standard criteria. 22 Enterococcus faecalis or E. faecium) were not considered as a putative causation of bacterial pneumonia. When more than 2 pathogenetically significant bacteria were identified in the same BAL sample, the term "mixed flora" was used. Yeast belonging to Candida spp were not considered as co-infective agents. In contrast, probable/proven pulmonary IA diagnosed at the time of CARV LRTD was considered as a fungal co-infection. The detection of CMV DNA in the BAL by RT-PCR was not considered as a co-pathogen entity in this study since it is a quite common phenomenon and its interpretation is still uncertain. 24

All allo-HSCT recipients received broad-spectrum antibiotics (carbapenems or cefepime or piperacilline-tazobactam). In cases of hemodynamic instability, akimacin was added. At the time of microbiological results, antimicrobial therapy was adapted accordingly.

The primary objective of the study was to describe the clinical and 

The clinical and biologic characteristics of CARVs LRTD are shown in Table 2 . The most common type of CARVs detected was EvRh in 32 (33%) cases, followed by RSV in 27 (28%), HPiV in 21 (22%), influenza in 16 (17%), HMPV in 13 (14%), ADV in 6 (6%), and CoV in 6 cases (6%). Seventy-four (75%) of the CARVs LRTD occurred within the first year after allo-HSCT. Twenty-two (23%) cases occurred before day +30 after stem cells infusion while 17 (18%) developed LRTD from day +30 to day +100 and 35 (36%) from day +100 until a

year. We did not observe significant clinical and/or biological differences among groups 1, 2, 3, and 4 except for a lower rate of CMV DNAemia-RAT in the group 2 (P = .04).

Univariate and multivariate analyses for RFs of CARVs LRTD bacterial-virus co-infection and for day 60 all causes mortality were shown in Table 3 . 3, and 4 were 77%, 67%, 35%, and 73%, respectively (P = .012),

( Figure 3A ). with gram-negative bacteria (P = .05). In cases 3 and 4, respectively, we found mixed flora in the BAL. The ICU admission rates were 40% and 53% (P = .7) while mortality rates were 65% and 38%, for group 3 and 5, respectively (P = .1). Day 60 OS was higher for group 5 when compared to group 3, although significance was not reached ( Figure 3 ). When we limited the analysis to those recipients with gram-negative bacteria we observed that 13 out of 20 recipients (65%) in group 3 die at day 60 after BAL compared to 4 of 15 (34%)

in group 4 (P = .1).

The study herein shows that CARVs LRTD co-infections are common after allo-HSCT. Bacterial pneumonia co-infection in recipients with CARVs LRTD was associated with increased mortality. We also With nucleic acid amplification testing, we report a high rate (47%) of CARV LRTD co-infections considered as respiratory virus, IA, and significant bacterial co-infection. Prior studies, before the RT-PCR era, reported lower co-infection rates (<30%) in BAL samples. 5, 9, 28, 29 This fact has limited the knowledge regarding the role of co-infections in the clinical outcome of CARVs LRTD.

Some studies have reported that pooled co-infections (bacteremia, fungal infections, CMV reactivations, herpes simplex virus, human herpesvirus 6, and Epstein-Barr virus) significantly increased mortality of allo-HSCT recipients in several CARV types, 5,7-10 but others failed to demonstrate such a negative effect. 29 In such reports, there is a lack of comparisons with mono-infections counterpart. In our study we provided evidence that CARVs LRTD with bacterial co-infections displayed a negative effect in mortality in multivariate analysis. Interestingly, we observed a trend to poorer outcome of recipients with CARVs LRTD and bacterial co-infections compared to those with bacterial pneumonia mono-infection. These findings suggest that the negative effect of bacterial co-infection does not seem to be independently explained by the predominant influence of the bacterial agent but rather by the co-infection status. When we limited the analysis to gram-negative bacilli, we also observed higher mortality of CARV LRTD with gram-negative bacterial co-infection (65%) compared to gram-negative bacterial pneumonia mono-infection (26%), although significance was not reached probably due to the low number of recipients included.

Another relevant finding of this study was the identification of 3

RFs for mortality easily identifiable at the time of CARVs LRTD. These

RFs have already been identified as prognostic markers for progression to LRTD (ie, lymphopenia) in several studies among different respiratory virus or as RFs for mortality (ie, lymphopenia <0.5 × 109/L, oxygen requirement, and CMV DNAemia-RAT). 5, 6, [9] [10] [11] [29] [30] [31] With these 3 RFs we built a risk score that was able to discriminate 3 groups with different risk of mortality irrespective of the co-infective status that merit to be validated in further studies. In contrast, we were not able to provide evidence of the clinical usefulness of neither, the ISI score nor the adapted Basel Immunodeficiency grading score, in predicting mortality in multivariate analysis in our pooled CARVs LRTD cohort. Although the ISI, originally designed for RSV, has been validated in influenza virus, 32 it is likely that co-infections, not included in the ISI, have hampered its ability to predict outcome in our series.

In fact, none of the variables included in the ISI were statistically significant in our uni-and multivariate model reflecting the weakness of this model in our cohort. This fact suggests that validation of the ISI in other CARVs is warranted before its routine application for therapeutic decision-making. Regarding the Basel Immunodefciency grading score, the fact that we did not include immunoglobulin levelsin the score may have hampered our ability to assess its true value and further validation would be required. 12, 13 Regarding the analysis of RFs for co-infections during CARVs LRTD our decision of limiting this analysis to bacterial co-infection was justified by 3 main reasons. First, our study showed that bac- of CARV LRTD co-infection. 38 We acknowledge that our study has some limitations including the relatively low number of patients, the use of 2 different multiplex PCR platforms for CARV, the inclusion of several CARV types, as well as its retrospective nature. In addition, when multiple viruses were detected we were not able to differentiate be- 

The authors declare that they have no conflict of interests. 

Management of RSV infections in adult recipients of hematopoietic stem cell transplantation

Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients

Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature

The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation

Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time

Viral infections-Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow

Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality

Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies

Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome

Virus infection facilitates the development of severe pneumonia in transplant patients with hematologic malignancies

Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Community-acquired respiratory paramyxovirus infection after allogeneic hematopoietic cell transplantation: a single-center experience

Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation

Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL

Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens

A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the

Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia

Comparative evaluation of the QIAsymphony RGQ system with the easyMAG/R-gene combination for the quantitation of cytomegalovirus DNA load in whole blood

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

Incidence, RF, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation

Clinical manifestations of graft-versushost disease in human recipients of marrow from HL-A-matched sibling donors

ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials

Non-parametric estimation from incomplete observations

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis

Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy

Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome

Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections

Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center

Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: application of an Immunodeficiency Scoring Index

A role for IFN-alpha beta in virus infection-induced sensitization to endotoxin

Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophageexpressed TNF-related apoptosis-inducing ligand

Adenovirus infection dramatically augments lipopolysaccharide-induced TNF production and sensitizes to lethal shock

An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation

Human cytomegalovirus: latency and reactivation in the myeloid lineage

Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT

Management of respiratory viral infections in hematopoietic cell transplant recipients

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections